HER2+ Breast Cancer | Specialty

The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.

Tucatinib Boosts Survival in HER2+ Breast Cancer, FDA Submission Imminent

December 12th 2019

Adding tucatinib to trastuzumab (Herceptin) and capecitabine (Xeloda) reduced the risk of death by 34% in heavily pretreated patients with unresectable locally advanced or metastatic HER2-positive breast cancer.

T-DXd Shows Potential to Establish New Standard of Care in Advanced HER2+ Breast Cancer

December 11th 2019

Trastuzumab deruxtecan (T-DXd; DS-8201) induced a confirmed objective response rate of almost 61% and a durable benefit in heavily pretreated patients with advanced HER2-positive breast cancer.

Dr. Hamilton on the KATHERINE Trial in HER2+ Breast Cancer

December 3rd 2019

Erika P. Hamilton, MD, discusses the results of the phase III KATHERINE trial in HER2-positive breast cancer.

Exciting Advances Continue in HER2+ Breast Cancer and Other Subtypes

November 20th 2019

Kurt W. Tauer, MD, FACP, discusses encouraging updates across the spectrum of breast cancer subtypes.

Research Efforts in HER2+ Breast Cancer Focused on Optimizing Novel Agents

November 19th 2019

Gregory Vidal, MD, PhD, discussed the ways in which currently available and investigational agents are being evaluated in the curative and metastatic settings of HER2-positive breast cancer.

Adjuvant T-DM1 Approaches EU Approval for HER2+ Early Breast Cancer

November 15th 2019

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of trastuzumab emtansine for the adjuvant treatment of adult patients with HER2-positive early breast cancer who have residual invasive disease (breast and/or lymph nodes) following neoadjuvant taxane-based chemotherapy and HER2-targeted therapy.

Dr. Vidal on Potential of [Fam-] Trastuzumab Deruxtecan in HER2+ Breast Cancer

November 15th 2019

Gregory Vidal, MD, PhD, discusses the potential of [fam-] trastuzumab deruxtecan in HER2-positive breast cancer.

Pivotal Data in HER2+ Breast Cancer Transform Paradigm

November 13th 2019

Erika P. Hamilton, MD, discussed several studies in the HER2-positive breast cancer space and the sequencing challenges that have emerged.

Dr. Gogineni on Implications of the APT Trial in HER2+ Breast Cancer

November 12th 2019

Keerthi Gogineni, MD, MSHP, discusses the clinical implications of the phase II APT trial in HER2-positive breast cancer.

Dr. O'Regan on Prognostic Value of pCR in HER2+ Breast Cancer

November 9th 2019

Ruth O’Regan, MD, discusses the prognostic value of pathologic complete response in HER2-positive breast cancer.

Margetuximab Elicits Modest Survival Extension in HER2+ Breast Cancer

October 24th 2019

The combination of margetuximab and chemotherapy induced a 1.8-month median overall survival increase in patients with pretreated HER2-positive metastatic breast cancer compared with trastuzumab (Herceptin) and chemotherapy.

Tucatinib Triplet Improves Survival in Advanced HER2+ Breast Cancer

October 21st 2019

Tucatinib combined with trastuzumab and capecitabine improved overall survival and progression-free survival compared with trastuzumab/capecitabine alone in heavily pretreated patients with locally advanced unresectable or metastatic HER2-positive breast cancer.

Dr. Marks on Investigational Antibody-Drug Conjugates in HER2+ Breast Cancer

October 21st 2019

Douglas K. Marks, MD, discusses investigational antibody–drug conjugates in HER2-positive breast cancer.

Dr. Anders on Sequencing Strategies in the Setting of HER2+ Brain Metastases

October 17th 2019

Carey Anders, MD, medical director, Brain and Spine Metastasis Program, and medical oncologist, Duke Cancer Institute, discusses sequencing strategies in the setting of HER2-positive breast cancer with brain metastases.

FDA Grants Trastuzumab Deruxtecan Priority Review for HER2+ Breast Cancer

October 17th 2019

The FDA has granted a priority review designation to a biologics license application for [fam-] trastuzumab deruxtecan (DS-8201) for the treatment of patients with HER2-positive metastatic breast cancer.

Dr. Bhave on Promising Anti-HER2 Agents in HER2+ Breast Cancer

October 16th 2019

Manali Bhave, MD, an assistant professor in the Department of Hematology and Medical Oncology at Winship Cancer Institute, Emory University School of Medicine, discusses promising anti-HER2 agents in metastatic HER2-positive breast cancer.

Safety Analysis Supports Adjuvant T-DM1 Use in Early HER2+ Breast Cancer

October 14th 2019

Michael Untch, MD, PhD, discusses the primary findings from the phase III KATHERINE trial and the added impact of long-term safety data regarding the use of adjuvant T-DM1 in early-stage HER2-positive breast cancer.

Dr. Westbrook on Combatting Tumor Heterogeneity in HER2+ Breast Cancer

October 9th 2019

Kelly E. Westbrook, MD, discusses combatting tumor heterogeneity in patients with HER2-positive breast cancer.

Lead KATE2 Author Suggests Atezolizumab Benefits HER2+ Breast Cancer Subgroup

October 8th 2019

Leisha A. Emens, MD, PhD, discusses the rationale behind the KATE2 study and the results that may signal clinical significance.

Dr. Anders Discusses the Use of Neratinib/Capecitabine for HER2-Positive Brain Metastases

October 8th 2019

Carey Anders, MD, director, Brain and Spine Metastasis Program, Duke Cancer Institute, discusses the use of neratinib (Nerlynx) and capecitabine in patients with HER2-positive breast cancer that has metastasized to the brain.